journal article·2022-03-02

A Nanoarchitectonic Approach Enables Triple Modal Synergistic Therapies To Enhance Antitumor Effects

Zhimin Mo, Qiuting Li, Kan Zhao, Qi Xu, Han Hu, Xu Chen, Yuxuan Luo, Bin Chi, Liping Liu, Xiefan Fang, Guangfu Liao, Zushun Xu, Jing Wang, Shengli Yang

Publisher page

Abstract

Improvement of antitumor effects relies on the development of biocompatible nanomaterials and combination of various therapies to produce synergistic effects and avoid resistance. In this work, we developed GBD-Fe, a nanoformulation that effectively integrated chemotherapy (CT), chemodynamic therapy (CDT), and photothermal therapy (PTT). GBD-Fe used gold nanorods as photothermal agents and encapsulated doxorubicin to amplify Fe3+-guided CDT effects by producing H2O2 and reducing the intracellular glutathione levels. In vitro and in vivo experiments were conducted to demonstrate the enhanced accumulation and antitumor effects of this tripronged therapy under magnetic resonance imaging (MRI) guidance. This tripronged approach of CT/CDT/PTT effectively induced tumor cytotoxicity and inhibited tumor growth in tumor-bearing mice and therefore represents a promising strategy to effectively treat tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Ministry of Education Key Laboratory for the Green Preparation and Application of Functional Materials, Hubei Key Laboratory of Polymer Materials, School of Materials Science and Engineering, Hubei University, Wuhan, Hubei 430062, China

Department of Oncology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China

Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Department of Hepatobiliary and Pancrease Surgery, Shenzhen People’s Hospital (The Second Clinical Medical College Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong 518020, China

Department of Toxicology, Charles River Laboratories, Inc., Reno, Nevada 89511, United States

Engineering Research Center of Nano-Geomaterials of Ministry of Education, China University of Geosciences, Wuhan 430074, China

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Funding

National Natural Science Foundation of China · China University of Geosciences · Key Laboratory of Biological Targeted Therapy, the Ministry of Education

References (60)

Show source-provided references
1. 10.1039/D1TB01629F10.1039/D1TB01629F ↗
2. 10.1038/s41467-018-03705-y10.1038/s41467-018-03705-y ↗
3. 10.1016/j.pmatsci.2020.10066610.1016/j.pmatsci.2020.100666 ↗
4. 10.3322/caac.2165410.3322/caac.21654 ↗
5. 10.1002/adma.20160248610.1002/adma.201602486 ↗
6. 10.1016/j.jcis.2021.12.07110.1016/j.jcis.2021.12.071 ↗
7. 10.1007/s40843-019-1397-010.1007/s40843-019-1397-0 ↗
8. 10.1002/adfm.20200621610.1002/adfm.202006216 ↗
9. 10.1016/j.trecan.2016.10.01610.1016/j.trecan.2016.10.016 ↗
10. 10.1186/s12951-021-01003-210.1186/s12951-021-01003-2 ↗
11. 10.1002/adma.20200689210.1002/adma.202006892 ↗
12. 10.1002/adma.20180827810.1002/adma.201808278 ↗
13. 10.1021/jacs.9b0345710.1021/jacs.9b03457 ↗
14. 10.1002/adma.20170168310.1002/adma.201701683 ↗
15. 10.1021/jacs.8b0871410.1021/jacs.8b08714 ↗
16. 10.1021/acsami.0c0443810.1021/acsami.0c04438 ↗
17. 10.1002/anie.20160550910.1002/anie.201605509 ↗
18. 10.1002/advs.20180198610.1002/advs.201801986 ↗
19. 10.1002/anie.20171014410.1002/anie.201710144 ↗
20. 10.1016/j.cell.2017.09.02110.1016/j.cell.2017.09.021 ↗
21. 10.1021/acsnano.9b0903210.1021/acsnano.9b09032 ↗
22. 10.1021/jacs.7b1111410.1021/jacs.7b11114 ↗
23. 10.1080/10826068.2017.134226710.1080/10826068.2017.1342267 ↗
24. 10.1038/nnano.2017.5810.1038/nnano.2017.58 ↗
25. 10.1126/sciadv.aax134610.1126/sciadv.aax1346 ↗
26. 10.1038/s41586-019-1730-110.1038/s41586-019-1730-1 ↗
27. 10.1038/s41598-017-12060-910.1038/s41598-017-12060-9 ↗
28. 10.1038/nature2518310.1038/nature25183 ↗
29. 10.1038/nrd.2018.16910.1038/nrd.2018.169 ↗
30. 10.1038/nature0357910.1038/nature03579 ↗
31. Ellerby L. M. · J. Neurochem. · 1996 · 67 · 125910.1046/j.1471-4159.1996.67031259.x ↗
32. 10.1038/s43018-019-0020-z10.1038/s43018-019-0020-z ↗
33. 10.1158/0008-5472.CAN-15-290810.1158/0008-5472.CAN-15-2908 ↗
34. 10.1016/j.nano.2013.04.00210.1016/j.nano.2013.04.002 ↗
35. 10.1002/adma.20200321010.1002/adma.202003210 ↗
36. 10.1016/j.cej.2018.09.13910.1016/j.cej.2018.09.139 ↗
37. 10.1016/j.apsusc.2020.14761510.1016/j.apsusc.2020.147615 ↗
38. 10.1002/adma.20160208010.1002/adma.201602080 ↗
39. 10.1039/C9EE00717B10.1039/C9EE00717B ↗
40. 10.1021/acsami.0c2030310.1021/acsami.0c20303 ↗
41. 10.1016/j.biomaterials.2019.01.04410.1016/j.biomaterials.2019.01.044 ↗
42. 10.1021/acsanm.8b0035910.1021/acsanm.8b00359 ↗
43. 10.1002/anie.20201687210.1002/anie.202016872 ↗
44. 10.1002/anie.20190488010.1002/anie.201904880 ↗
45. 10.1002/adma.20080092110.1002/adma.200800921 ↗
46. 10.1039/C8TB00148K10.1039/C8TB00148K ↗
47. 10.1016/j.jcis.2021.03.17310.1016/j.jcis.2021.03.173 ↗
48. 10.1021/acsnano.1c0548510.1021/acsnano.1c05485 ↗
49. 10.1021/acsnano.8b0639910.1021/acsnano.8b06399 ↗
50. 10.1021/bi00323a00710.1021/bi00323a007 ↗
51. 10.3390/molecules2207110610.3390/molecules22071106 ↗
52. 10.1016/j.actbio.2017.03.05510.1016/j.actbio.2017.03.055 ↗
53. 10.1021/acs.nanolett.0c0364110.1021/acs.nanolett.0c03641 ↗
54. 10.1016/S0022-2860(02)00256-910.1016/S0022-2860(02)00256-9 ↗
55. 10.1039/c3an00787a10.1039/c3an00787a ↗
56. 10.1016/j.ijpharm.2008.07.00610.1016/j.ijpharm.2008.07.006 ↗
57. 10.1021/nn304332s10.1021/nn304332s ↗
58. 10.1007/s12272-020-01204-710.1007/s12272-020-01204-7 ↗
59. 10.1002/EXP.2021000910.1002/EXP.20210009 ↗
60. 10.1002/adfm.20160134110.1002/adfm.201601341 ↗